Early treatment with Voraxaze® (glucarpidase) resulted in significantly lower rates of toxicity and mortality.3,4
Patients treated with Voraxaze® experienced rapid and sustained reductions in plasma methotrexate (MTX) concentrations.1
Order Voraxaze® for general stock or expedited shipping to take immediate action against serious and potentially fatal systemic effects of HDMTX toxicity.
Recently published Consensus Guidelines recommend treatment with
Voraxaze® (glucarpidase) within 48 hours from the start of MTX infusion
for patients with delayed MTX clearance and acute kidney injury.5
Select CONTINUE to proceed to the BTG Pharmaceuticals website.